Making a difference to the people we help treat by creating value and improving healthcare outcomes through connecting innovative manufacturers with Australasian customers.

The 2023-24 Merck Analyte Quarterly Update is Here!

Products are for professional/laboratory use only.

Beyond Biomarkers! 

Expect reliable measurements, a simplified user experience, and knowledgeable scientific partners to help drive your biomarker projects. 

Merck’s high-quality and limitation-lifting immunoassay platforms, such as MILLIPLEX multiplex panels, single molecule count (SMCR) ultrasensitive (at femtograms/mL sensibility) immunoassays, ELISAs and RIAs, provide you with all the AssayAbilities to take your biomarker research further.

The table below, from Analyte Quarterly 2023-24, highlights the new assays introduced by Merck.


Milliplex Panels

Description

Species

Cat No.

Acute Phase Protein Panel 

Porcine

PAPP1-160K

Acute Phase Protein Panel 

Bovine

BAPP1-150K

Complement C5b-9 Singleplex 

Human

HC5B9-140K

Panel A + B Combo Pack 76-Plex

Human

HCYTPAB-76SK

Panel A + B Combo Pack 96-Plex

Human

HCYTPAB-96SK


SMC Kits

Description

Species

Cat No.

PD-1 High Sensitivity Immunoassay Kit

Human

03-0207-00

PD-L1 High Sensitivity Immunoassay Kit 

Human

03-0208-00


 

2023-24 Merck Analyte Quarterly Update

Download Here >

Learn MILLIPLEX Multiplex assay tips and tricks with this user guide

Download Here >



Request a Quote

Request Quote

Recent Posts

Roche – New KAPA NGS Reagents

Roche KAPA kits offer a range of high-performance products for molecular biology applications in next-generation sequencing (NGS). KAPA RNA EvoPrep Kit The KAPA RNA EvoPrep…

Read full article

2027 Abacus dx Emerging Investigators Grant

COMING SOON Grant in Research Funding Empowering the Next Generation of Scientific Leaders Stay tuned for the 2027 Abacus dx Emerging Investigators Grant. More information…

Read full article

Developing Diagnostic Kits for Ovarian Cancer

In Australia, ovarian cancer is the deadliest reproductive cancer. The average five‑year survival rate sits at around 49%, compared with about 92% for breast cancer,…

Read full article